<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8044C2F3-70A8-44B3-A919-3A5ADEFD2311"><gtr:id>8044C2F3-70A8-44B3-A919-3A5ADEFD2311</gtr:id><gtr:name>Francis Crick Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37EF6C9C-5F51-40DD-BED5-B792981BC119"><gtr:id>37EF6C9C-5F51-40DD-BED5-B792981BC119</gtr:id><gtr:name>Imperial Cancer Research Fund</gtr:name><gtr:address><gtr:line1>44 Lincoln's Inn Fields</gtr:line1><gtr:postCode>WC2A 3PX</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8044C2F3-70A8-44B3-A919-3A5ADEFD2311"><gtr:id>8044C2F3-70A8-44B3-A919-3A5ADEFD2311</gtr:id><gtr:name>Francis Crick Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BCC422F-7C18-4B19-BE51-DD5BC6EA1741"><gtr:id>6BCC422F-7C18-4B19-BE51-DD5BC6EA1741</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Le Quesne</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_1203%2F1"><gtr:id>E5D34966-9A72-45F7-ACC5-DB688EF9D4C0</gtr:id><gtr:title>Cellular toxicity and translational control in pulmonary epithelial cells</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_1203/1</gtr:grantReference><gtr:abstractText>This project is designed to identify exactly how the chemicals in cigarette affect which genes are turned on or off in human lung cells. This will reveal in fine detail exactly how cigarette smoke affects the behaviour of these cells, and will give clues as to how cigarette smoking leads to disease in human cells. It will also enable us to learn a great deal about how toxic chemicals affect a process called translation, which is the step at which the genetic code is converted into protein; this process is highly regulated, but is only now starting to be properly studied in human diseases.
Genes which are affected by cigarette smoke will be assessed as markers of disease processes in archived human lung tissue. Also, we will look at how translation is altered in lung cancer compared to more normal cultured human cells. This is potentially of great value to the treatment of lung cancer, as a number of drugs are capable of targeting the translation process directly, and there is the possibility of using these to treat lung cancer.</gtr:abstractText><gtr:technicalSummary>There is a lack of information to show how exposure to environmental toxins changes gene expression patterns. A greater understanding of these pathways is important for a number diseases that are associated with environmental exposure and the lung is particularly important in this regard. It is planned that cigarette smoke will be used at the toxicant since cigarette smoking is linked to a host of diseases, both malignant and non-malignant, and many constituents of cigarette smoke are known mutagens. However, little is known of the direct effects of smoking upon gene expression, especially at the level of translation, and how these effects may influence disease progression. Elucidation of these mechanisms will shed light on the aetiology of smoking-related disease, and will hopefully lead to novel therapeutic targets as well as prognostic and diagnostic markers for toxic exposure.
This project will use mRNA and polysome profiling techniques to identify mRNAs that are up- down-regulated lung epithelial cells in response to cigarette smoke using an already established cell culture model. The assays used will address both total mRNA abundance (by conventional mRNA profiling) and polysomal abundance (ie translational activity, by polysome profiling and/or ribosome footprinting).. Patterns of gene expression re-programming following smoke exposure will be detailed in both transformed and normal-like lung epithelial cell lines.
In this way we will identify groups of mRNAs that respond to smoke exposure at the level of translation. We will then seek to relate these changes to several disease phenotypes- e.g. metaplasia, pro-inflammatory and fibrogenic changes. We will also seek to identify pathways the up- or down-regulation of which are related to smoke exposure, either transcriptionally or translationally. These will be validated at the protein level (by Western blot, and also by immunohistochemistry in archival formalin-fixed tissue), and investigated as possible interventional targets in cell culture and ultimately in animal models.
In addition to this, we will identify patterns of translational dysregulation, and dysregulated single mRNAs, that occur in tumour vs normal tissues.</gtr:technicalSummary><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-06-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1607805</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PEACE</gtr:description><gtr:id>9E7F57A8-44D6-4E12-9718-7A3DA340DF38</gtr:id><gtr:impact>Successful funding application to CRUK (accelerator award).</gtr:impact><gtr:outcomeId>56e0403bda3fe1.89799436-2</gtr:outcomeId><gtr:partnerContribution>Overall project management.</gtr:partnerContribution><gtr:piContribution>Expert pathology input, assistance with preparation &amp;amp; funding interview.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Radiotoxicity in lung tumours</gtr:description><gtr:id>F46F8B6F-F105-4529-A5CA-656388F38E08</gtr:id><gtr:impact>Establishment of a programme of research (PhD project) within my funded programme.</gtr:impact><gtr:outcomeId>56e03e394d0951.51517197-1</gtr:outcomeId><gtr:partnerContribution>Expert input re genotoxicity of radiation and detailed knowledge/understanding of DNA repair mechanisms.</gtr:partnerContribution><gtr:piContribution>I am co-supervising a PhD student, and providing expert histopathological support as well as access to tissues and liaison with other clinical specialties.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>PEACE</gtr:description><gtr:id>70FD981B-A9AD-4CF6-A2FC-7A3D966A90B3</gtr:id><gtr:impact>Successful funding application to CRUK (accelerator award).</gtr:impact><gtr:outcomeId>56e0403bda3fe1.89799436-1</gtr:outcomeId><gtr:partnerContribution>Overall project management.</gtr:partnerContribution><gtr:piContribution>Expert pathology input, assistance with preparation &amp;amp; funding interview.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Francis Crick Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>co-ISH IHC</gtr:description><gtr:id>7ACF43C1-772A-4A8C-A4BB-3BF73225601B</gtr:id><gtr:impact>Novel methodology for the simultaneous detection and quantification of mRNA and protein from the same gene in archival tissues.</gtr:impact><gtr:outcomeId>56e04f43678385.03269588-1</gtr:outcomeId><gtr:partnerContribution>Technical expertise.</gtr:partnerContribution><gtr:piContribution>Supply of tissue, expert pathology input.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TraceRx</gtr:description><gtr:id>9AC64DDC-A36A-4F5A-84B1-EE97817B94E4</gtr:id><gtr:impact>Publication. multidisciplinary- basic scientists, clinicians, pathologists.</gtr:impact><gtr:outcomeId>56e03f9d9ed381.72644618-2</gtr:outcomeId><gtr:partnerContribution>Project management
DNA sequencing, preaparation of manuscripts</gtr:partnerContribution><gtr:piContribution>Lead pathologist
Expert input in establishment of SOPs, data forms
Day-to-day histopathological input
Tissue sampling</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Oncology</gtr:department><gtr:description>TraceRx</gtr:description><gtr:id>D23F276A-49EC-467A-AA2F-0F0C84F2FA0B</gtr:id><gtr:impact>Publication. multidisciplinary- basic scientists, clinicians, pathologists.</gtr:impact><gtr:outcomeId>56e03f9d9ed381.72644618-1</gtr:outcomeId><gtr:partnerContribution>Project management
DNA sequencing, preaparation of manuscripts</gtr:partnerContribution><gtr:piContribution>Lead pathologist
Expert input in establishment of SOPs, data forms
Day-to-day histopathological input
Tissue sampling</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Berlin microenvironment meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9AF4562B-791E-45FC-B02C-F1CB22E07CEB</gtr:id><gtr:impact>I attended an excellent meeting on the tumour microenvironment in Berlin. I presented my data as a poster, and made valuable links with many experts in the field.</gtr:impact><gtr:outcomeId>58c16977b71608.80494740</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Tumour microenvironment meeting (Montana)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>42A18DBF-D7AA-4B9D-85BE-1441D467554B</gtr:id><gtr:impact>Keystone meeting on the tumour microenvironment. I gave a poster presentation and made many invaluable contacts, and learned a great deal about a field in which we are developing active interests.</gtr:impact><gtr:outcomeId>58c169170a5f73.19167575</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>AZ meeting in Gothenburg</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>4F92E7F7-2019-4490-8DEE-6AB4D9342DAA</gtr:id><gtr:impact>A visit to my collaborators in AstraZeneca to discuss work on RNA therapeutic agents. The eventual outcome was funding of a small project to develop in situ assays for therapeutic RNA-related toxicities.</gtr:impact><gtr:outcomeId>58c198802b9fa7.44421507</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>TRUK 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3293A8AF-EDDE-4AFD-BC7F-7449A230E52C</gtr:id><gtr:impact>Talk well received, generated interest, questions, and discussion afterwards.

Discussions following the talk suggested a number of useful additional experiments.</gtr:impact><gtr:outcomeId>54636397dcfde5.50381283</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lung cancer conference (Denver)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2BF2481E-5BDE-4371-A4B8-CB7CB9BB0A58</gtr:id><gtr:impact>Talk to a pathology session of the IASLC meeting to 50+ delegates, on the molecular evolution of lung cancer. There were interesting questions afterwards.</gtr:impact><gtr:outcomeId>56e042a41812c3.74048721</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://wclc2015.iaslc.org/</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Translational Control of Cancer meeting (SF)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9F152E81-E78D-4E3F-A350-D52D1149AD12</gtr:id><gtr:impact>This was an international scientific conference. I presented my work, and had invaluable discussions with many experts in the field.</gtr:impact><gtr:outcomeId>58c169d8ed10f1.98168705</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISH meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F74B4726-2956-47D1-93A0-6CAA57486C35</gtr:id><gtr:impact>Invited speaker at an international meeting of experts in the field of in situ hybridisation. There were several interesting questions, and a collaboration has resulted from the meeting.</gtr:impact><gtr:outcomeId>56e0487bd7b553.87222749</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI talk, Liverpool</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E7A1143D-8EE1-44A1-AFD6-9B90392E9AD8</gtr:id><gtr:impact>I was invited to speak at the NCRI conference in Liverpool, on biomarkers for immunotherapy in lung cancer. My talk was well received, with interesting questiona and very good feedback.</gtr:impact><gtr:outcomeId>58c16a42c3b918.39123701</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MEPs visit (Leicester)</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AF85815A-3DAC-4F12-9019-8DA09B81848D</gtr:id><gtr:impact>Meeting and discussion with a local MP and MEP, in which the importance of exposure to environmental inhaled carcinogenic toxins was prominent.</gtr:impact><gtr:outcomeId>56e047edc16382.23603743</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BTOG</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>378EDEB0-F172-4383-B5E1-3B9A47B99528</gtr:id><gtr:impact>Presentation of several posters at this major annual meeting of lung cancer clinicians.</gtr:impact><gtr:outcomeId>56e0478c6cc843.18596680</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School visit (Oakham)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>32B235ED-8925-4F88-9693-C8EA66804361</gtr:id><gtr:impact>Invited to attend Oakham school's science fair, and to interact with students through the evening. All students studying science subjects at A level or equivalent attended a talk and dinner. I spoke to several students directly about careers in academic medicine, and shared my details with them should require future advice/laboratory experience.</gtr:impact><gtr:outcomeId>58c167d4154d42.88424017</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Pulmonary Pathology Club</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CC0C0D85-C404-4D2A-B6DB-C46FF004A43C</gtr:id><gtr:impact>I organized a one-day conference meeting of the Pulmonary Pathology Club, a UK-wide clinical and academic organisation. The meeting was excellent, with several very high quality talks and spirited debate. Several areas of clinical practice were discussed, as were impacts of recent scientific discoveries upon clinical interpretation.</gtr:impact><gtr:outcomeId>58c1991156fab6.72411948</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ENSEMBL 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>6619F2FD-D277-403F-B68A-412DA1AA96BD</gtr:id><gtr:impact>My talk generated a lot of very useful discussion and networking afterwards.

I made very valuable contacts with researchers in the US and Japan, and have since started a formal collaboration and exchanged some physical research materials.</gtr:impact><gtr:outcomeId>54636422cd30e0.25127696</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CRUK mesothelioma workshop</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3F544276-DFFF-4D3E-B64E-6173C0F478FC</gtr:id><gtr:impact>CRUK working group to discuss the way forward in mesothelioma research. I was invited to give a talk focussing on issues of tumour biology, microenvironment, and biomarkers in mesothelioma to a group of mesothelioma research leaders and funders. It was a very useful day indeed, and yielded several interesting leads for future work.</gtr:impact><gtr:outcomeId>58c1689bb6ffa6.79819857</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Pathology Conference 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>ED897480-2529-4442-A47E-17D4302A2D44</gtr:id><gtr:impact>The talk stimulated questions and discussion.

After the talk, I had enquiries from trainee pathologists about research opportunities.</gtr:impact><gtr:outcomeId>54636487b00928.48367192</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Talk to UK trainee pathologists talk 2014</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>25C70D4E-C797-414D-BCA2-D1B6A662D649</gtr:id><gtr:impact>There were several questions about training in academic pathology.

The talk was followed up by emails and inquiries into research training.</gtr:impact><gtr:outcomeId>54636515417184.72225525</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>20000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of multiplex assays for the quantification of translational stress responses in human and animal tissues</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>AstraZeneca</gtr:fundingOrg><gtr:id>C814D982-750E-4C8F-85E9-F43BEC59F9B7</gtr:id><gtr:outcomeId>58c167038e4413.46058129</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>125478</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development Gap Fund</gtr:description><gtr:end>2016-10-02</gtr:end><gtr:fundingOrg>MRC Technology (MRCT)</gtr:fundingOrg><gtr:fundingRef>A856/3037</gtr:fundingRef><gtr:id>0D382737-D80E-4E98-832A-F4926A9949F3</gtr:id><gtr:outcomeId>56e041c181e3a9.74644749</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Targeting LARP1 to overcome acquired treatment resistance in cancer</gtr:description><gtr:end>2018-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>D43598D5-7908-447B-9409-B07799798898</gtr:id><gtr:outcomeId>58c16692bfd302.09697297</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>1000 archival cases of surgically resected lung adenocarcinomas from our local archive were identified. Clinicopathological data, including survival data, has been collected on all cases. Archival tissue sections have beeen scanned into a high-resolution digital archive. Archival tissue blocks have been assembled into highly annotated tissue microarrays.</gtr:description><gtr:id>EA74A8CA-4CEA-4AF4-A01D-DDA451C56289</gtr:id><gtr:impact>The collection is starting to yield significant insights into tumour biology.</gtr:impact><gtr:outcomeId>56e0502abb6745.63163387</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Adenocarcinoma collection</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>We and our collaborators have collected clinicopathological data and archival tissue from 400 surgical mesothelioma cases. The construction of tissue microarrays is underway, and data from several sources have already been collected and are now being combined into a single resource.</gtr:description><gtr:id>4DDDEC28-ADA4-4A51-846B-AC2EDD00BB56</gtr:id><gtr:impact>The first TMAs have already been subjected to in situ analyses by our collaborators, and the data are being developed into a manuscript.</gtr:impact><gtr:outcomeId>58c196c9df7825.24524485</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Mesothelioma collectin</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have developed the capacity to simultaneously apply immunohistochemistry and in situ hybridisation for the protein and mRNA products of a given gene. This means that we can, for any given tissue, derive a measure of the translational efficiency of a gene of interest on a single cell basis.
We use immunofluorescent methods for both arms of the assay, and simultaneously apply assays for other proteins of interest, eg those which we believe to be involved in translational control.
In this way we are able to demonstrate how translational control is altered in different tissue compartments, and how it varies between and within tumours.</gtr:description><gtr:id>B6C8DAD4-65CA-491C-9742-3E46DFFD7FC4</gtr:id><gtr:impact>We have been able to provide direct in situ evidence of translational reprogramming in human tumour tissue. These preliminary data have been used to support a CRUK funding application, and will be orally presented at an upcoming in situ hybridiastion meeting.</gtr:impact><gtr:outcomeId>58c195f912d881.36595313</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Quantitative co-ISH IHC</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>055B3B4A-0432-45C8-AC1C-D7010F2D7453</gtr:id><gtr:title>A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material.</gtr:title><gtr:parentPublicationTitle>Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a40c671927e79fbfb121ffe5c687b698"><gtr:id>a40c671927e79fbfb121ffe5c687b698</gtr:id><gtr:otherNames>Le Quesne J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1556-0864</gtr:issn><gtr:outcomeId>546361cf8ff621.82803060</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3012179-81A7-4E92-802A-CB9C781C80E2</gtr:id><gtr:title>Corrigendum: Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4554e2051f9b323489c56abb888aea6a"><gtr:id>4554e2051f9b323489c56abb888aea6a</gtr:id><gtr:otherNames>Abbosh C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5aa94efa89b4b2.01205242</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AEBB2001-57FD-461D-8F4C-EE265FFD2DFE</gtr:id><gtr:title>Tracking genomic cancer evolution for precision medicine: the lung TRACERx study.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3324dd043ac960b370ef51b0cf7efb0b"><gtr:id>3324dd043ac960b370ef51b0cf7efb0b</gtr:id><gtr:otherNames>Jamal-Hanjani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>546361cfb4d8f8.02056617</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0830930F-1A22-413B-A505-FF1E4270181E</gtr:id><gtr:title>UTRly malignant: mRNA stability and the invasive phenotype in&amp;nbsp;breast cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a40c671927e79fbfb121ffe5c687b698"><gtr:id>a40c671927e79fbfb121ffe5c687b698</gtr:id><gtr:otherNames>Le Quesne J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>546362c2505169.41417659</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A67D2B1F-D035-43D1-8B38-94A814147A9C</gtr:id><gtr:title>Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78e832cdb4a7a87bd201090a445fe197"><gtr:id>78e832cdb4a7a87bd201090a445fe197</gtr:id><gtr:otherNames>Hiley CT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn><gtr:outcomeId>58c16246a9d079.67368360</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A3EAB298-C60A-4989-AD92-F785C7DE6059</gtr:id><gtr:title>The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dab45632b603a036db857c8e5980decb"><gtr:id>dab45632b603a036db857c8e5980decb</gtr:id><gtr:otherNames>Modelska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dfeb122a1280.00540032</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC45871F-F866-4C02-822F-5FE289E65594</gtr:id><gtr:title>Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays.</gtr:title><gtr:parentPublicationTitle>Applied immunohistochemistry &amp; molecular morphology : AIMM</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57b80904c355370b7f21ec586a15ccd9"><gtr:id>57b80904c355370b7f21ec586a15ccd9</gtr:id><gtr:otherNames>Blows FM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1533-4058</gtr:issn><gtr:outcomeId>56dfeb11a0a3d9.66552373</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>73AA12D3-E5D4-4C30-B500-89310A21C238</gtr:id><gtr:title>Resistance to HSP90 inhibition involving loss of MCL1 addiction.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32b9ab54e2703e237771e4986faa150a"><gtr:id>32b9ab54e2703e237771e4986faa150a</gtr:id><gtr:otherNames>Busacca S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>56dfeb11c55522.78593372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>859C95BD-129B-4361-A534-54B7EA81E36D</gtr:id><gtr:title>Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/71cecfb754bf4c54930c301d27537efd"><gtr:id>71cecfb754bf4c54930c301d27537efd</gtr:id><gtr:otherNames>Raza F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>56dfeb114dc8f0.35418957</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34062938-A88A-4695-A35E-3FB97F02ACDA</gtr:id><gtr:title>Tracking the Evolution of Non-Small-Cell Lung Cancer.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3324dd043ac960b370ef51b0cf7efb0b"><gtr:id>3324dd043ac960b370ef51b0cf7efb0b</gtr:id><gtr:otherNames>Jamal-Hanjani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>5a9fecf5163bb8.20754143</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5169889F-50DA-4C47-9CE9-51CD4A4F2507</gtr:id><gtr:title>The molecular approach to diagnosis in lung cancer.</gtr:title><gtr:parentPublicationTitle>British journal of hospital medicine (London, England : 2005)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0a216d2def58429028dbaff655349407"><gtr:id>0a216d2def58429028dbaff655349407</gtr:id><gtr:otherNames>Moore DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1750-8460</gtr:issn><gtr:outcomeId>56dfeb1172e020.99430057</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CCFC332-9F43-4399-8A94-5ADA85D5BCD9</gtr:id><gtr:title>Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ec6b80f20e1552cb41c9aec70915b06"><gtr:id>5ec6b80f20e1552cb41c9aec70915b06</gtr:id><gtr:otherNames>Kolluri KK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5a9fecf4b52b76.32245081</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6C8E990-7849-4B75-8B6F-9E8E6219BDDD</gtr:id><gtr:title>Partial restoration of protein synthesis rates by the small molecule ISRIB prevents neurodegeneration without pancreatic toxicity.</gtr:title><gtr:parentPublicationTitle>Cell death &amp; disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4c6af0c38a78606ae062de8c732b1e0"><gtr:id>d4c6af0c38a78606ae062de8c732b1e0</gtr:id><gtr:otherNames>Halliday M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>56dfeb11ef9ba4.03574241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6518B896-7BDF-4259-AD7D-42FF1DA029EA</gtr:id><gtr:title>Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.</gtr:title><gtr:parentPublicationTitle>Nature</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4554e2051f9b323489c56abb888aea6a"><gtr:id>4554e2051f9b323489c56abb888aea6a</gtr:id><gtr:otherNames>Abbosh C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0028-0836</gtr:issn><gtr:outcomeId>5a9fecf55feaa2.41860647</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>11F72ED1-4ADB-4306-B516-BCA4F2A1C895</gtr:id><gtr:title>Long-Fiber Carbon Nanotubes Replicate Asbestos-Induced Mesothelioma with Disruption of the Tumor Suppressor Gene Cdkn2a (Ink4a/Arf).</gtr:title><gtr:parentPublicationTitle>Current biology : CB</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/42dd50d6a147ddbe48323bf4f1e247da"><gtr:id>42dd50d6a147ddbe48323bf4f1e247da</gtr:id><gtr:otherNames>Chernova T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0960-9822</gtr:issn><gtr:outcomeId>5a9fecf4de32c6.29359303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D2EE65A-9F9C-42A9-B25F-50A977112657</gtr:id><gtr:title>Explant Cultures of Non-Small Cell Lung Carcinoma Enable Evaluation of Primary Tumor Responses to Anticancer Therapy.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bb21aa48b34d485576459cda583d6cbe"><gtr:id>bb21aa48b34d485576459cda583d6cbe</gtr:id><gtr:otherNames>Karekla E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>58c165cf97cfd9.00968843</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA995D0D-FD3D-4298-883D-1490C2ECAAB3</gtr:id><gtr:title>MicroRNA in situ hybridization in tissue microarrays.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17988fe92db4b2071ff971f669f40424"><gtr:id>17988fe92db4b2071ff971f669f40424</gtr:id><gtr:otherNames>Turnock-Jones JJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>546361cfe18906.35954814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7344C965-1855-4516-B60B-E9C4DCDF5EF0</gtr:id><gtr:title>eIF4A alleviates the translational repression mediated by classical secondary structures more than by G-quadruplexes.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa1c599d5c25ff586fff88e785e1423b"><gtr:id>aa1c599d5c25ff586fff88e785e1423b</gtr:id><gtr:otherNames>Waldron JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>5a9fecf48971e2.79947814</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_1203/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>